-

Agilent to Participate in Goldman Sachs 43rd Annual Global Healthcare Conference

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the company will participate in the Goldman Sachs 43rd Annual Healthcare Conference on Wednesday, June 15, in Rancho Palos Verdes, California.

President and CEO Mike McMullen and Chief Financial Officer Bob McMahon will represent the company in a fireside chat that begins at 10 a.m. PT/1 p.m. ET. A link to the live event will be available on Agilent’s investor relations website and a replay will be provided within 24 hours after the event.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in the life sciences, diagnostics, and applied chemical markets, delivering insight and innovation toward advancing the quality of life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.32 billion in fiscal 2021 and employs 17,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn, Twitter and Facebook.

Contacts

INVESTOR CONTACT:
Parmeet Ahuja
+1 408 345 8948
parmeet_ahuja@agilent.com

MEDIA CONTACT:
Sarah Litton
+1 669 255 7696
sarah.litton@agilent.com

Industry:

AGILENT TECHNOLOGIES INC

NYSE:A
Details
Headquarters: Santa Clara, California, USA
CEO: Padraig McDonnell
Employees: 18000
Organization: PUB
Release Versions
English

Contacts

INVESTOR CONTACT:
Parmeet Ahuja
+1 408 345 8948
parmeet_ahuja@agilent.com

MEDIA CONTACT:
Sarah Litton
+1 669 255 7696
sarah.litton@agilent.com

Social Media Profiles
Agilent on LinkedIn
More News From AGILENT TECHNOLOGIES INC

Agilent xCELLigence RTCA Instrumentation Applied in Recent FDA Approval

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) is pleased to announce its role in supporting Autolus Therapeutics’ FDA approval for AUCATZYL®, a recently approved CAR T therapy. Agilent's advanced cell analysis instrumentation, specifically the xCELLigence Real-Time Cell Analysis (RTCA) technology, was applied in developing and validating AUCATZYL. The xCELLigence RTCA technology supported the development and implementation of the potency assay. By providing precise a...

CORRECTING and REPLACING Agilent to Showcase Next-Generation Digital Pathology Solutions at USCAP 2025

SANTA CLARA, Calif.--(BUSINESS WIRE)--Please replace the release with the following corrected version due to multiple revisions to the fifth paragraph. The updated release reads: AGILENT TO SHOWCASE NEXT-GENERATION DIGITAL PATHOLOGY SOLUTIONS AT USCAP 2025 Agilent Technologies Inc. (NYSE: A) is excited to announce its participation at the upcoming United States and Canadian Academy of Pathology (USCAP) Conference, which will be held March 22-27, 2025, in Boston. At the conference, Agilent will...

Agilent Research Catalyst Award Presented to Columbia University for Professor Pawel Muranski

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that Columbia University has received an Agilent Research Catalyst (ARC) Award on behalf of Dr. Pawel Muranski, an internationally recognized researcher and physician-scientist specializing in bone marrow transplant (BMT) and cancer cellular immunotherapy. Dr. Muranski is the Director of Cellular Immunotherapy Laboratory at Columbia University Irving Medical Center. He is also an Assistant Professor of Med...
Back to Newsroom